A Phase III, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)
Clinical Trial Information
Trial Contact: Clinical Trial Referral Office
Trial Phone: 321-841-7246
Principal Investigator: Jacobo Hincapie-Echeverri, MD
Phase: III
Age Group: ADULTOLDER_ADULT
ClinicalTrials.gov ID: NCT07585266
Objective
To evaluate the efficacy (clinical activity) of velzatinib compared with imatinib in previously untreated participants with metastatic and/or unresectable GIST, as evidenced by PFS